Preclinical Alzheimer's Disease Therapeutics

摘要: In 2013, the Food and Drug Administration released draft guidance on drug development for early-stage Alzheimer's disease (AD). This builds understanding that AD is a progressive with symptoms appearing long after neurodegeneration has begun. Preclinical relies conceptual distinction made between presence of pathological processes clinically observable symptoms. With advent new biomarkers allow presymptomatic detection pathology, there now exists an opportunity to design conduct clinical trials putative disease-modifying drugs in earliest stages when they are thought have greatest chance success. As such, four planned or underway secondary prevention AD.